49 results on '"Rong, Haojing"'
Search Results
2. Discovery of KT-474a Potent, Selective, and Orally Bioavailable IRAK4 Degrader for the Treatment of Autoimmune Diseases.
3. Prediction of pharmacokinetics and pharmacodynamics in human for IRAK4 targeted protein degrader
4. Discovery of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates Targeting MYD88 Mutant Diffuse Large B‑Cell Lymphoma.
5. Protein Engineering on Human Recombinant Follistatin: Enhancing Pharmacokinetic Characteristics for Therapeutic Application
6. Development of Guanfacine Extended-Release Dosing Strategies in Children and Adolescents with ADHD Using a Physiologically Based Pharmacokinetic Model to Predict Drug–Drug Interactions with Moderate CYP3A4 Inhibitors or Inducers
7. Myostatin and activin blockade by engineered follistatin results in hypertrophy and improves dystrophic pathology in mdx mouse more than myostatin blockade alone
8. Functional Properties of Hop Polyphenols
9. STAT3 degraders inhibit cellular activation, cytokine production, and Th17 development, resulting in inhibition of autoimmunity in the MOG-EAE model of CNS inflammation.
10. Correction to: Development of Guanfacine Extended-Release Dosing Strategies in Children and Adolescents with ADHD Using a Physiologically Based Pharmacokinetic Model to Predict Drug–Drug Interactions with Moderate CYP3A4 Inhibitors or Inducers
11. A First-in-Class STAT3 Degrader KT-333 in Development for Treatment of Hematologic Cancers
12. Applicability of Parallel μLC for Achiral Method Development and Impurity Profiling in Support of Pharmaceutical Early Development
13. IRAK4 degradation abrogates cytokine release and improves disease endpoints in murine models of IL-33/36- as well as Th17-driven inflammation
14. Using Simcyp to project human oral pharmacokinetic variability in early drug research to mitigate mechanism-based adverse events
15. Mechanisms of the Anti-Tumor Activity of STAT3 Degraders in Lymphoma
16. Abstract LB-088: A STAT3 selective targeted protein degrader decreases the immunesuppressive tumor microenvironment and drives antitumor activity in preclinical models
17. Abstract 5222: Degraders targeting both IRAK4 and IMiD substrates show combinatorial effects leading to broader activity with durable and complete regressions in MYD88 mutant lymphoma xenografts in vivo
18. Leveraging Quantitative Systems Pharmacology Approach into Development of Human Recombinant Follistatin Fusion Protein for Duchenne Muscular Dystrophy
19. Targeted Delivery of Small Interfering RNA (siRNA) to Proximal Tubule Cells in the Kidneys
20. Abstract C054: Discovery of KYM-003, a potent and selective STAT3 degrader with antitumor activity in heme malignancies
21. Small Molecule-Induced, Selective STAT3 Degradation Leads to Anti-Tumor Activity in STAT3-Dependent Heme Malignancies
22. Abstract LB-272: KYM-001, a first-in-class oral IRAK4 protein degrader, induces tumor regression in xenograft models of MYD88-mutant ABC DLBCL alone and in combination with BTK inhibition
23. 490c – C1Inh: A Novel Therapeutic Target to Treat Biliary Atresia and Liver Fibrosis
24. 8-Prenylnaringenin, the phytoestrogen in hops and beer, upregulates the function of the E-cadherin/catenin complex in human mammary carcinoma cells
25. In vitro metabolic and transporter profiling for maribavir (SHP620)
26. Targeted Degradation of IRAK4 Protein Via Heterobifunctional Small Molecules for Treatment of MYD88 Mutant Lymphoma
27. Quantitative Translational Analysis of Brain Kynurenic Acid Modulation via Irreversible Kynurenine Aminotransferase II Inhibition
28. Discovery of a novel Kv7 channel opener as a treatment for epilepsy
29. Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective
30. Correction to: Development of Guanfacine Extended-Release Dosing Strategies in Children and Adolescents with ADHD Using a Physiologically Based Pharmacokinetic Model to Predict Drug–Drug Interactions with Moderate CYP3A4 Inhibitors or Inducers
31. Development of Guanfacine Extended-Release Dosing Strategies in Children and Adolescents with ADHD Using a Physiologically Based Pharmacokinetic Model to Predict Drug–Drug Interactions with Moderate CYP3A4 Inhibitors or Inducers
32. In vitro and in vivo effects of 2,4 diaminoquinazoline inhibitors of the decapping scavenger enzyme DcpS: Context-specific modulation of SMN transcript levels
33. Design of Potent mRNA Decapping Scavenger Enzyme (DcpS) Inhibitors with Improved Physicochemical Properties To Investigate the Mechanism of Therapeutic Benefit in Spinal Muscular Atrophy (SMA)
34. Understanding Lung Deposition of Alpha-1 Antitrypsin in Acute Experimental Mouse Lung Injury Model Using Fluorescence Microscopy
35. Quantitative measurements of GDF-8 using immunoaffinity LC-MS/MS
36. 5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5-(( S)-1-Acetyl-2,3-dihydro-1 H-indol-2-ylmethoxy)-3- tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-1 H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679)—A potent FLAP inhibitor
37. Demystifying Brain Penetration in Central Nervous System Drug Discovery
38. Integrated Approaches to Blood-Brain Barrier
39. 5-Lipoxygenase-Activating Protein (FLAP) Inhibitors. Part 4: Development of 3-[3-tert-Butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic Acid (AM803), a Potent, Oral, Once Daily FLAP Inhibitor
40. 5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5-((S)-1-Acetyl-2,3-dihydro-1H-indol-2-ylmethoxy)-3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-1H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679)—A potent FLAP inhibitor
41. 5-Lipoxygenase-Activating Protein Inhibitors: Development of 3-[3-tert-Butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic Acid (AM103)
42. High‐throughput logP measurement using parallel liquid chromatography/ultraviolet/mass spectrometry and sample‐pooling
43. Determination of the Hop-Derived Phytoestrogen, 8-Prenylnaringenin, in Beer by Gas Chromatography/Mass Spectrometry
44. Identification of Isoflavones in the Roots ofPueraria lobata
45. Narrow-bore HPLC analysis of isoflavonoid aglycones and theirO- andC-glycosides frompueraria lobata
46. Demystifying Brain Penetrationin Central NervousSystem Drug Discovery.
47. Identification of Isoflavones in the Roots of Pueraria lobata
48. Narrow-bore HPLC analysis of isoflavonoid aglycones and their O- and C-glycosides from pueraria lobata.
49. Quantitative measurements of GDF-8 using immunoaffinity LC-MS/MS.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.